white → purple2
Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
UR-144
UR-144 is a synthetic cannabinoid of the tetramethylcyclopropyl indole class, sold as a novel psychoactive substance. It was created by Abbott Laboratories in 2006 as a candidate cannabinoid receptor agonist medication, and shares part of its structure with JWH-018, substituting a tetramethylcyclopropyl group for that compound's naphthyl. It acts at CB1 and CB2 receptors, producing cannabis-like effects that some users describe as more psychedelic than other synthetic cannabinoids. Little information about its activity is available.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Moderate2.5-20 mg
Duration
Onset10 minutes
Total1-2 hours
Subjective Effects
Subjective Effects not written up yet
Pharmacology
Pharmacodynamics
UR-144 acts as an agonist at both CB1 and CB2 cannabinoid receptors, with the limited available data indicating full agonism at each. It is distinguished among synthetic cannabinoids by an apparent bias toward CB2 over CB1, though it remains clearly psychoactive. In mice, UR-144 produces locomotor suppression, antinociception, hypothermia, and catalepsy, and it generalizes to THC in drug discrimination testing; those discriminative effects are blocked by the CB1 antagonist rimonabant.
Pharmacokinetics
CYP3A4 appears to be the most important metabolic route for UR-144. When the compound is heated, such as during inhalation, it forms a pyrolysis product, 1-(1-pentyl-1H-indol-3-yl)-3-methyl-2-(propan-2-yl)but-3-en-1-one.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance not written up yet
Harm Potential
Harm Potential not written up yet
History & Culture
UR-144 was created in 2006 by Abbott Laboratories as a candidate cannabinoid receptor agonist medication. The compound was found to be biased toward CB2 over CB1, a profile regarded as favourable for therapeutic development. Data on the compound was published in 2010, and it is also known under the…
Legality
Legality not written up yet
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the UR-144 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.